Quick Answer
Foghorn Therapeutics Inc. reported Net Income of -$74.28 million for fiscal year 2025.
Foghorn Therapeutics Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$74.28M | +14.2% |
| 2024 | -$86.62M | +12.0% |
| 2023 | -$98.43M | +9.6% |
| 2022 | -$108.88M | -7.5% |
| 2021 | -$101.32M | -47.3% |
| 2020 | -$68.80M | -34.6% |
| 2019 | -$51.13M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$15.85M | +17.1% | +11.6% |
| June 30, 2025 | -$17.94M | +21.9% | +4.8% |
| March 31, 2025 | -$18.83M | +24.7% | +1.5% |
| September 30, 2024 | -$19.12M | -33.3% | +16.8% |
| June 30, 2024 | -$22.98M | +22.1% | +8.1% |
| March 31, 2024 | -$25.02M | +17.9% | -74.4% |
| September 30, 2023 | -$14.35M | +44.3% | +51.4% |
| June 30, 2023 | -$29.49M | -8.0% | +3.3% |
- Foghorn Therapeutics Inc. showed an increase of +14.2% in Net Income compared to the prior fiscal year.
- Over the 2019–2025 period, Foghorn Therapeutics Inc.’s net income has declined by 45.3% (from -$51.13 million to -$74.28 million).
- The most recent figure is from Foghorn Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: